Question

Is anyone here working on any studies pertaining to Low Dose Naltrexone?

Naltrexone was approved by the FDA in 1984 in a 50mg dose for the purpose of helping heroin or opium addicts, by blocking the effect of such drugs. By blocking opioid receptors, naltrexone also blocks the reception of the opioid hormones that our brain and adrenal glands produce: beta-endorphin and metenkephalin. Many body tissues have receptors for these endorphins and enkephalins, including virtually every cell of the body's immune system"
Jan 9, 2012

Topics

0 / 0  ·  2 Answers  ·  66 Views

All Answers (2)

  • Kirsten Hansen
    I would also be interested in any studies going on. Specifically in relation to its use in individuals with autoimmune disorders and any concern over long term use on adrenal gland processes.
    Jan 9, 2012

Question Followers (4)